About AggreDYNE
AggreDYNE is a Healthcare company based in Houston (United States) founded in 2011. Platelet stickiness is measured using patented Aggreguide A-100. AggreDYNE has raised $3 million across 1 funding round. AggreDYNE offers products and services including AggreGuide A-100. Its focus areas include Life Sciences, Hematology, In Vitro Diagnostics Tests and Platelet Function Analyzers. Its legal entity is AgoraDyne, Inc. Its competitors include Accumetrics and ThrombusCheck; 1 of its 2 listed competitors has raised funding.
Company details
AggreDYNE was founded in 2011 and is headquartered in Houston, United States. Operations center on platelet function monitoring in the medical diagnostics sector. The patented Aggreguide A-100 device is employed to assess blood platelet stickiness and evaluate responses to anti-platelet therapies, such as aspirin and ADP inhibitors. Distribution occurs through 16 partners spanning 38 countries.
- Headquarters Houston, United States
- SectorsHealthcare
- Email••••••••
- Website aggredyne.com
- Social LinkedIn X Facebook
- Legal Name Agoradyne, Inc.
- Total Equity Funding$3M (USD)
in 1 rounds
- Latest Funding Round$3M (USD), Series A
Apr 2012
Products & Services of AggreDYNE
AggreDYNE offers a comprehensive portfolio of products and services, including AggreGuide A-100.
System for assessing platelet function using light scattering technology.
Funding Insights of AggreDYNE
AggreDYNE has successfully raised a total of $3M through 1 strategic funding round. The most recent funding activity was a Series A round of $3 million completed in April 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 1
- Last Round Series A — $3M
- First Round $3M
(Apr 2012)
All 1 funding rounds of AggreDYNE with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2012 | $3M | Series A | – | – | – |
Timeline of AggreDYNE
2 dated milestones of AggreDYNE across 1 years, from founding to its latest funding, stage changes and deals.
- Founded AggreDYNE is founded.
- Funding First funding round of $3.0M.
Competitors of AggreDYNE
AggreDYNE has 2 listed competitors in our database, 1 of them funded. They include Accumetrics and ThrombusCheck.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| accumetrics.com | 1996 | San Diego, United States | $97.53M | 46 | Platelet function assays and coagulation systems are developed and marketed. | |
| thrombuscheck.com | 2017 | Palo Alto, United States | Offers a device that mimics plaqued arteries for personalized anti-platelet therapy. |
Detailed competitors of AggreDYNE
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Hematology
3 companies that operate in the same segment as AggreDYNE (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aggredyne
Complete news archive for AggreDYNE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AggreDYNE
AggreDYNE was founded in 2011 and raised its 1st funding round 1 year after it was founded.
AggreDYNE is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
AggreDYNE is a funded company, having raised a total of $3M across 1 funding round to date. The company's 1st funding round was a Series A of $3M, raised on Apr 2012.
AggreDYNE was founded in 2011 and is headquartered in Houston, United States. Operations center on platelet function monitoring in the medical diagnostics sector. The patented Aggreguide A-100 device is employed to assess blood platelet stickiness and evaluate responses to anti-platelet therapies, such as aspirin and ADP inhibitors. Distribution occurs through 16 partners spanning 38 countries.
AggreDYNE's top competitors include Accumetrics and ThrombusCheck.
AggreDYNE offers AggreGuide A-100.
AggreDYNE operates through Agoradyne, Inc..